Viramune is an antiviral medicine used to treat people infected with human immunodeficiency virus type 1 (HIV\-1\), a virus that causes acquired immune deficiency syndrome (AIDS). It is used in combination with at least two other antiviral medicines. Viramune contains the active substance nevirapine.
Therapeutic Indication
**Viramune 50 mg/5 mL oral suspension** **and** **200 mg tablets** Viramune is indicated in combination with other anti\-retroviral medicinal products for the treatment of HIV\-1 infected adults, adolescents, and children of any age. Most of the experience with Viramune is in combination with nucleoside reverse transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune should be based on clinical experience and resistance testing. **Viramune 400 mg prolonged\-release tablets** Viramune is indicated in combination with other anti\-retroviral medicinal products for the treatment of HIV\-1 infected adults, adolescents, and children three years and above and able to swallow tablets (see section 4\.2\). Prolonged\-release tablets are not suitable for the 14\-day lead\-in phase for patients starting nevirapine. Other nevirapine formulations, such as immediate\-release tablets or oral suspension should be used (see section 4\.2\). Most of the experience with Viramune is in combination with nucleoside reverse transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune should be based on clinical experience and resistance testing (see section 5\.1\).
Therapeutic Area (MeSH)
ATC Code
J05AG01
ATC Item
N/A
Pharmacotherapeutic Group
Antivirals for systemic use
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| nevirapine | N/A | nevirapine |
EMA Name
Viramune
Medicine Name
Viramune
Aliases
N/ANo risk management plan link.
